Cetera Advisors LLC Mannkind Corp Transaction History

Cetera Advisors LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$3.25 - $5.27 $435 - $706	-134 Reduced 1.28%	10,300 $46,000
Q4 2023 Feb 13, 2024	SELL	$3.34 - $4.29 $180 - $231	-54 Reduced 0.51%	10,434 $37,000
Q3 2023 Nov 14, 2023	BUY	$3.91 - $5.45 $211 - $294	54 Added 0.52%	10,488 $43,000
Q2 2023 Aug 09, 2023	BUY	$3.72 - $4.79 $38,814 - $49,978	10,434 New	10,434 $42,000
Q3 2022 Nov 10, 2022	SELL	$2.99 - $4.35 $8,970 - $13,049	-3,000 Reduced 22.39%	10,400 $32,000
Q2 2022 Aug 11, 2022	BUY	$2.67 - $4.77 $35,778 - $63,917	13,400 New	13,400 $51,000
Q1 2022 May 12, 2022	SELL	$2.62 - $4.45 $40,610 - $68,975	-15,500 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$4.05 - $5.37 $62,775 - $83,235	15,500 New	15,500 $68,000

245

148M

1.62M

802K

Ticker MNKD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 257,338,000
Market Cap $1.81B
Description
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocri...

Get notified when there are updates to the investment portfolio of Cetera Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Cetera Advisors LLC with notifications on news.